

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : A61K 39/395 // (A61K 39/395 A61K 31:705)	A1	(11) International Publication Number: WO 93/07899 (43) International Publication Date: 29 April 1993 (29.04.93)
(21) International Application Number: PCT/GB92/01884 (22) International Filing Date: 14 October 1992 (14.10.92) (30) Priority data: 775,598 15 October 1991 (15.10.91) US 9215749.4 24 July 1992 (24.07.92) GB (60) Parent Application or Grant (63) Related by Continuation US 775,598 (CIP) Filed on 15 October 1991 (15.10.91) (71) Applicant (for all designated States except US): THE WELL- COME FOUNDATION LIMITED [GB/GB]; Unicorn House, 160 Euston Road, London NW1 2BP (GB).		(72) Inventors; and (75) Inventors/Applicants (for US only) : WALDMANN, Her- man [GB/GB]; HALE, Geoffrey [GB/GB]; The Uni- versity of Cambridge, Department of Pathology, Tennis Court Road, Cambridge CB2 1QP (GB). (74) Agent: BAKER-MUNTON, Nicola, Jane; The Wellcome Foundation Limited, Langley Court, Beckenham, Kent BR3 3BS (GB). (81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL MEDIATED INFLAMMATION OF THE JOINTS (57) Abstract The invention relates to the use of an antibody recognising the CDw52 antigen for the treatment of T-cell mediated inflam- mation of the joints, in particular for the treatment of rheumatoid arthritis. Preferably the antibody is the humanised antibody CAMPATH-1H which may be used together with another immunosuppressive antibody or an immunosuppressive agent such as a steroid.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NQ	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SK	Slovak Republic
CI	Côte d'Ivoire	LK	Sri Lanka	SN	Senegal
CM	Cameroon	LU	Luxembourg	SU	Soviet Union
CS	Czechoslovakia	MC	Monaco	TD	Chad
CZ	Czech Republic	MG	Madagascar	TG	Togo
DE	Germany	ML	Mali	UA	Ukraine
DK	Denmark	MN	Mongolia	US	United States of America
ES	Spain			VN	Viet Nam
FI	Finland				

CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL
MEDIATED INFLAMMATION OF THE JOINTS

5 The present invention relates to the manufacture of a
medicament for the treatment of certain auto-immune
conditions in a human or animal subject.

10 The cells and molecules in an animal body do not
normally stimulate an adaptive immune response in that body
as a result of a number of mechanisms which ensure a state
referred to as "self-tolerance". However, in certain
circumstances these mechanisms may fail to prevent the
stimulation of such an immune response and this condition
is referred to as "auto-immunity". A number of diseases in
humans and animals are now thought to result from auto-
15 immunity.

One such condition is rheumatoid arthritis, a common,
progressive and crippling disease, which is associated with
the production by an animal of antibodies against its own
IgG. The inflammation of and consequent damage to the
20 joints associated with the disease are probably mediated
via immune complexes. Diseases in which inflammation of
and damage to the joints arise from auto-immunity are
referred to generically herein as "T-cell mediated
inflammation of the joints".

25 The CDw52 antigen (a 23kDa glycoprotein also referred
to as CAMPATH-1) is strongly expressed on the surface of
all human lymphocytes and most monocytes but is absent from
other blood cells including stem cells. A number of
antibodies have been developed directed against CDw52 which
30 is an unusually good target for complement-mediated attack.
Antibodies against CDw52 bind to all lymphocytes and
monocytes but lyse only lymphocytes (T and B) in vivo.
Antigens similar to CDw52 are expressed in other mammalian
species.

35 Antibodies which have been developed against CDw52 and
which have been used in therapy include the following:

CAMPATH-1M is a rat IgM monoclonal antibody which has been used extensively in vitro for purging bone marrow harvests in order to deplete the T cell population prior to bone marrow transplantation. Marked reductions in the incidence and severity of graft-versus-host disease has
5 been seen with this therapy.

CAMPATH-1G is a rat IgG2b class-switch variant of an IgG2a antibody recognising the CDw52 antigen which has been used in vivo to achieve immunosuppression in more than 100
10 patients undergoing organ and bone marrow transplantation, management of organ rejection and treatment of haematologic malignancies with a high level of success. However, the rapid development of an anti-rat immunoglobulin response, including the possibility of anaphylaxis, is likely to
15 limit the use of rat monoclonal antibodies against the CDw52 antigen in humans in vivo.

CAMPATH-1H is a genetically manipulated IgG antibody obtained by grafting the complementarity determining regions from CAMPATH-1G into human framework regions. The
20 resulting "humanized" antibody is highly effective in vitro being equivalent to the rat monoclonal antibody at complement lysis and two to four times better in cell-mediated lysis of human lymphocytes. No limiting anti-globulin response is anticipated with this humanized
25 antibody.

Expression of CAMPATH-1H was achieved initially in rat myeloma cells by placing DNA encoding the engineered antibody chains in genomic context under control of the immunoglobulin promoter/enhancer. CAMPATH-1H has recently
30 been expressed to high levels in Chinese hamster ovary (CHO) cells.

It has now surprisingly been found that antibodies against the CDw52 antigen are effective in the treatment of T-cell mediated inflammation of the joints.

35 The present invention provides the use of an antibody recognising the CDw52 antigen for the manufacture of a

medicament for the treatment of a human or animal subject suffering from T-cell mediated inflammation of the joints.

The present invention also provides a method of treatment of a human or animal subject suffering from T-cell mediated inflammation of the joints which comprises
5 administering to the said subject an effective amount of an antibody recognising the CDW52 antigen.

The method according to the invention is applicable to the treatment of any disease involving T-cell mediated
10 inflammation of the joints. The most common such disease is rheumatoid arthritis which is a major cause of suffering and disability in the developed world. Other diseases involving T-cell mediated inflammation of the joints include variants of rheumatoid arthritis such as atypical
15 Still's disease. The method according to the invention will find most applicability in the treatment of humans but it may also find application in veterinary medicine where animals with disease involving T-cell mediated inflammation of the joints may also be treated with an appropriate
20 antibody.

For the treatment of humans it is preferred to use an anti-CDW52 antibody which does not carry with it the risk of the development of an immune reaction against the antibody itself. Accordingly whilst it is possible to use
25 mouse or rat mono-clonal antibodies it is preferred to use antibodies which have been produced by recombinant DNA technology and which have been engineered to reduce the risk of causing an immune reaction. Thus it is possible to use a chimeric antibody in which the constant domains of a
30 mouse or rat anti-CDW52 antibody have been replaced by the constant domains of a human antibody. However, it is preferred to use a humanized or CDR-grafted antibody for the treatment of humans, i.e. an antibody in which the complementarity determining regions from a mouse or rat
35 antibody are combined with framework regions and constant domains from one or more human antibodies.

Most preferably the method according to the invention is carried out using the CDR-grafted antibody CAMPATH-1H (see Riechmann et al, Nature, 322, 323-327 (1988)). As noted above, the antibody CAMPATH-1H can be produced in rat myeloma cells as originally described or it can be produced in any other expression system, particularly an expression system suitable for the production of a correctly folded, glycosylated, mammalian protein. High yields of CAMPATH-1H have been obtained by expression in a genetically manipulated CHO cell line (Page and Sydenham, Biotechnology, 9, 64-68 (1991)).

The dosages of anti-CDw52 antibody, preferably CAMPATH-1H, to be administered to a patient suffering from a disease involving T-cell mediated inflammation of the joints will vary with the condition being treated and the recipient of the treatment. The dose will generally be in the range 1 to about 100mg for an adult patient, usually administered daily for a period between 1 and 30 days. The preferred daily dose is 1 to 10mg per day although in some instances larger doses of up to 40mg per day may be used.

The anti-CDw52 antibody, particularly CAMPATH-1H will generally be administered to the patient in the form of a pharmaceutical formulation. Such formulations preferably include, in addition to the antibody, a physiologically acceptable carrier or diluent, possibly in admixture with one or more other agents such as other antibodies or drugs, such as an antibiotic. Suitable carriers include, but are not limited to, physiological saline, phosphate buffered saline, phosphate buffered saline glucose and buffered saline. Alternatively the antibody may be lyophilised (freeze dried) and reconstituted for use when needed by the addition of an aqueous buffered solution as described above. Routes of administration are routinely parenteral, including intravenous, intramuscular, subcutaneous and intraperitoneal injection or delivery.

The anti-CDw52 antibody may be administered in

combination with or sequentially with other drugs, in particular other drugs conventionally used in the treatment of T-cell mediated inflammation of the joints, such as immunosuppressive and/or anti-inflammatory agents. Typically, the immunosuppressive agents will include cyclosporin A or a purine analogue, e.g. methotrexate, 6-mercaptapurine, or the like. Suitable anti-inflammatory agents include steroids, for example hydrocortisones, such as prednisone, etc., or non-steroidal anti-inflammatory drugs, many of which are known to those skilled in the art.

Sequential administration of the antibody with another drug may be appropriate in some cases. For example, the anti-CDw52 antibody may re-establish the effectiveness of steroids in patients where steroid therapy has ceased to be effective so that treatment with the antibody may conveniently be followed by steroid therapy.

The anti-CDw52 antibody can also be administered in conjunction with another antibody having an immunosuppressive and/or tolerance inducing effect, for example anti-CD2, anti-CD3, anti-CD4 or anti-CD18 antibodies. One preferred treatment protocol according to the invention involves administration of an anti-CDw52 antibody such as Campath 1H together with or followed by administration of an anti-CD4 antibody. The administration of the antibodies may be supplemented by simultaneous or subsequent administration of a chemical therapeutic agent such as a steroid.

The invention is illustrated by the following case histories of patients treated with the CDR-grafted anti-CDw52 antibody CAMPATH-1H.

The anti-CDw52 antibody used in Case No. 1 was produced in rat Y-0 myeloma cells. The anti-CDw52 antibody used in the remaining cases was produced by expression in a recombinant CHO cell line (Page and Sydenham, Biotechnology, 9, 64-68 (1991)). In all cases the antibodies were extracted from the cell culture medium and

subsequently purified.

It is to be understood that these case histories are not intended to be in any way limiting on the scope of the invention.

5 CASE NO. 1

10 The patient was a female born in 1940 who was a typical case of a patient with severe aggressive rheumatoid arthritis who had failed to respond or had reacted adversely to several disease modifying anti-rheumatic drugs.

15 Immediately prior to commencement of treatment with CAMPATH-1H, the patient had restricted joint mobility and had shown a poor response to increasing doses of penicillamine which had been discontinued. Treatment with
20 CAMPATH-1H commenced September 1988 and the patient was given 12 doses of 2mg CAMPATH-1H intravenously in 500ml normal saline over a 14 day period. This brought about a "remarkable" subjective improvement in the condition of the patient. There was also an objective improvement based on
25 a number of conventional clinical criteria and in the sense that she was able to undertake her own self-care and also such activities as walking and knitting. The patient also received 500mg Naprosyn twice daily.

30 The treatment with CAMPATH-1H brought about a relatively long lasting lymphopenia. By about 20 weeks after treatment the patient's lymphocyte count had returned to above 1.0 which was matched by a reactivation of her disease. Treatment commenced with pyritinol (a second-line anti-rheumatic agent undergoing trials) and this treatment
35 was continued for 12 months. Treatment then commenced with cyclosporin 125mg daily and 25 months after the commencement of treatment with CAMPATH-1H the patient continues to do reasonably well on cyclosporin.

CASE NO. 2

35 The patient was a female born in 1971 who has been diagnosed as suffering from a particularly severe case of

atypical Still's disease (a variant of rheumatoid arthritis occurring in younger patients).

At the age of 15 (in 1986) she developed fever, a brief episode of nausea and vomiting and abdominal pain and then a painful red right ankle. She was admitted to hospital and a small amount of pus was extracted from the ankle joint. At the same time she was found to have a symmetrical synovitis, right hypochondrial pain, pleuritic pain and a rash. These have persisted intermittently ever since, the polyarthropathy being dominant and immobilising.

Over the period 1988 to 1990 various investigations showed anaemia (normochronic, normocytic), thrombocytosis, hyperglobulinaemia, abnormal liver function (both alkaline phosphatase and transferases), fluctuating creatinine clearances (possibly related to NSAID therapy), hypoalbuminaemia (without proteinuria), white cell scan (uptake in joints), respiratory function tests, ECG (inverted T waves), positive ANCA. ANA, DNAB, Rh factor, complement, bone scans have always been normal as were renal, liver and skin biopsies. A synovial biopsy in June 1990 showed a predominantly T cell infiltrate and peripheral subsets showed these to be mostly T also (T 80%, B 11%).

Therapies during the above period included steroids, penicillamine, azathioprine, cyclophosphamide, methotrexate, plasma exchange, high dose intravenous gamma-globulin and cyclosporin A. Partial control was achieved with steroids, plasma exchange and cyclosporin A but remissions proved to be short lived. The progression of her disease and her lack of response to conventional and aggressive therapy resulted in her being an inpatient in hospital for long periods during 1990.

The patient commenced treatment with CAMPATH-1H in December 1990 and she received 6 daily doses of 2mg each of CAMPATH-1H followed by 6 doses of 10mg each over a 7 day period. The antibody was administered intravenously in

saline. Towards the end of the treatment period a definite symptomatic improvement was noted and by the end of the treatment the patient's joints were less inflamed and she had a lower C-reactive protein value and thermographic index as well as lowered erythrocyte sedimentation rate. Shortly after the end of treatment she developed a skin abscess on her left thigh at the site of subcutaneous injection which was treated with antibiotics. Two and a half weeks after the end of treatment she changed from total parenteral nutrition to oral feeds. Four weeks after the end of treatment her condition was remarkably improved and she was discharged from hospital and allowed to return home. Steroid therapy was gradually reduced from the level prior to treatment with the antibody (30mg/day) so that five months after antibody therapy, the patient was receiving only 6mg/day prednisone and even this was subsequently withdrawn.

Approximately 9 months after the initial treatment, she suffered a relapse with multiple joint involvement. After initial testing for sensitivity with a low dose, she was given a further course of treatment of CAMPATH-1H at a dose of 8mg/day for 5 days and then 10mg/day for 20 days. The therapeutic response was good initially but the remission was relatively short lived and three months later she required further treatment.

CAMPATH-1H was given at 12mg/day for five days followed by 20mg/day of a rat derived human anti-CD4 antibody (Clone YNB46.1.8; IgG_{2b}, kappa light chain serotype; see Galfre *et al.*, Nature, 277, 131-133 (1979)). There was no sustained therapeutic effect and investigation showed the presence of an anti-idiotypic response to CAMPATH-1H. Plasma exchange was carried out in an attempt to lower the level of the anti-idiotypic antibody and the patient was treated again with the combination of CAMPATH-1H and the anti-CD4 antibody, this time with good effect. The patient was also treated with steroid therapy

(prednisone 10mg/day) and four months later was in stable remission.

CASES NOS. 3.1 to 3.8

5 In a small open study, eight patients (3.1 to 3.8) with rheumatoid arthritis were treated with CAMPATH-1H. In seven out of eight case, a short course of treatment elicited favourable therapeutic responses. In only one patient was there any sign of sensitisation, and the
10 resultant serological response was directed against a component of fetal calf serum (used in the manufacture of the antibody) and not against the humanised antibody itself.

15 Table 1 summarises the characteristics of the eight patients. All fulfilled the American Rheumatism Association criteria for RA and had active disease, as defined by 3 out of 4 of the following criteria: Ritchie articular index > 10, early morning stiffness > 45 minutes, ESR > 30 mm/hour, joint score > 10. Seven were
20 seropositive. Their disease had proved unresponsive to two or more second-line agents, and these had been stopped at least four weeks before entry into the trial. Patients were permitted to continue with non-steroidal anti-inflammatory drugs (NSAID) and an existing dose of
25 prednisolone (up to 20mg daily). There were otherwise healthy, and had normal renal and hepatic function.

30 Patients were admitted to hospital for antibody therapy. Therapeutic grade CAMPATH-1H was produced in Chinese hamster ovary (CHO) cells grown in hollow-fibre continuous culture system ('Acucyst-Junior', Endotronics Inc) and was purified on Protein A. It was formulated in phosphate-buffered saline and following sterility and endotoxin checks the antibody was stored at -30°C prior to administration.

35 The antibody was administered by intravenous infusion over a period of 2-4 hours, during which vital

signs were recorded every 15 minutes. A course of therapy lasted for 10 days, and consisted of 4mg of antibody for 5 days followed by 8mg of antibody for 5 days. Between daily infusions, patients were fully mobile but did not receive physiotherapy.

Ritchie articular index and joint score were assessed immediately before treatment, and daily during treatment, by a trained metrologist. Duration of morning stiffness, patient's global assessment (comprising the sum of 4 scores representing night pain, rest pain, general well-being and functional ability, each measured on a visual analogue scale), joint thermography, ESR, CRP and FBC with differential WCC were also recorded. A similar assessment was performed weekly after therapy for one month, and then monthly. Patients were judged to have relapsed if a further second-line agent, or an increase in prednisolone dose, was administered in an attempt to control symptoms.

Patient data were analysed using the Mann-Whitney Wilcoxon Rank test, comparing values after treatment with those on day 0. Patients were excluded from further analysis if additional prednisolone or a further second-line agent was administered (i.e. if they were judged to have relapsed). This was necessary to avoid the introduction of bias by these additional therapies.

The first infusion of CAMPATH-1H resulted in a rapid fall in total lymphocyte count in all patients. Lymphopenia was evident as early as one hour after the start of the first infusion, and at this time all patients developed systemic symptoms of fever (up to 40°C), rigors, nausea and, in one case, hypotension. These symptoms lasted for 2-3 hours. Lymphocyte counts remained suppressed for several months after therapy.

In seven patients there was an impressive initial response to therapy as evidenced by clinical reduction in joint swelling and improvement in thermography. In addition, there were statistically significant improvements

in Ritchie articular index and joint score lasting until day 125. Table 2 shows the pooled data for all patients and Table 1 also includes the duration of remission for individual responders, which was variable. Thus one patient (3.7) required additional therapy one month after antibody therapy, whereas another (3.5) continues to demonstrate benefit six months after treatment with sustained improvements in Ritchie index (1), morning stiffness (0 minutes), joint score (13) and global assessment (92). There was no improvement in the ESR or CRP with therapy, and no correlation between clinical relapse and lymphocyte count.

Apart from the first dose response and similar but milder symptoms following the second dose, therapy was well tolerated. The first two patients treated developed culture-negative mouth ulceration but this was not seen in subsequent patients given prophylaxis with a mixture of amphotericin and anti-bacterial mouthwashes. Mild Herpes simplex ulceration developed in patient 3.4 but responded to topical therapy with acyclovir. No adverse effects were noted on renal or hepatic function.

A weak "antiglobulin response" was detected in patient 3.5 at the end of therapy. Subsequent analysis showed that this could be adsorbed non-specifically by fetal calf serum suggesting a serological response to a component of this, rather than to CAMPATH-1H itself. Furthermore, it did not inhibit binding of CAMPATH-1H to transfectants expressing CDw52.

This is the first demonstration of an antibody treatment of rheumatoid arthritis without a significant antiglobulin response complicating the first course of therapy. The serological response measured in patient 3.5 was shown to be directed at a component of the antibody preparation other than CAMPATH-1H itself.

TABLE 1
Patients Characteristics at Start of Therapy

	Patient	Age	Disease duration	ESR (mm/hr)	CRP (mg/l)	Ritchie#	Joint score#	Morning stiffness (min)
5		(y)	(y)					
	3.1	32	2	100	160	10	17	30
	3.2	62	13	95	45	34	15	300
	3.3	69	9	64	112	36	16	120
10	3.4	46	16	48	45	22	12	45
	3.5	50	19	55	94	38	18	300
	3.6	61	35	40	90	34	11	5
	3.7	55	7	62	114	39	16	360
	3.8	68	3	80	128	27	12	60
15								
	Patient	Global assessment *	Rheumatoid factor (iu/ml)	Previous therapy **	Pred dose (mg/day)	Duration of Remission (Days)	Morning stiffness (min)	
	3.1	181	40	G,P,M,S	7.5	140		
20	3.2	286	2112	G,P,M,S, γ IFN	10	140		
	3.3	212	0	G,P,M,S,A,CyA	0	84		
	3.4	105	125	G,P,M,S	7.5	166		
	3.5	283	121	G,P,S,C	20	165 (well)		
	3.6	299	56	G,P,S,CyA	0	94		
25	3.7	298	420	G,P,M,S,C,Cy	10	37		
	3.8	175	233	S,Romazarit	0	126		

* Global assessment = sum of 4 scores (max = 100 each) measured on a 10cm visual analogue scale representing night pain, rest pain, general well-being and functional ability

** G = gold, P = penicillamine, M = methotrexate, S = sulphasalazine, γ IFN = γ -interferon, A = azathioprine, CyA = cyclosporine A, C = cyclophosphamide

*** well = still in remission at most recent follow-up

Maximum attainable Ritchie and joint scores were 78 and 26 respectively

TABLE 2

Summary of Clinical Outcome.

(Values are the median and range for each index at each time point).

5	Day#	0(8)	10(8)	28(8)
	Ritchie	34(10-39)	10.5(0-29)*	9.5(1-32)*
	Joint score	16(12-18)	7(1-14)*	8.5(2-14)*
	Morning stiffness (min)	90(5-360)	30(0-240)	10(0-300)
10	Global score	247(61-299)	86(4-318)	74(21-308)
	ESR (mm/hr)	58(40-100)	76(8-120)	61(20-120)
	CRP (mg/l)	103(45-160)	79(23-120)	63(23-108)
	Day#	56(7)	90(7)	125(5)
15	Ritchie	9.0(0-25)*	11.0(0-34)*	13(2-26)*
	Joint score	7(0-13)*	12(6-14)*	12(3-14)*
	Morning stiffness (min)	30(0-120)	60(0-120)	30(0-120)
	Global score	59(10-368)	126(4-395)	136(8-271)
	ESR (mm/hr)	66(16-104)	60(12-105)	84(26-110)
20	CRP (mg/l)	70(24-150)	81(54-212)	136(74-236)

* = significant at $p < 0.05$ by Mann-Whitney Wilcoxon Rank test.

number in brackets refers to patients remaining in study at each time point.

CLAIMS:

1. Use of an antibody recognising the CDw52 antigen for the manufacture of a medicament for the treatment of T-cell mediated inflammation of the joints.
5
2. Use according to Claim 1, wherein said antibody is a humanised antibody.
- 10 3. Use according to Claim 2, wherein said antibody is CAMPATH-1H.
4. Use according to any of Claims 1 to 3, for the manufacture of a medicament for the treatment of rheumatoid arthritis.
15
5. Use according to any of Claims 1 to 4, wherein in said treatment the antibody is administered in an amount of from 1 to about 100mg per day for a period between 1 and 30 days.
20
6. Use according to Claim 5, wherein said amount is 1 to 10mg per day.
- 25 7. Use according to any of Claims 1 to 6, wherein said medicament is adapted to be administered intravenously.
8. Use according to any of Claims 1 to 7, wherein the medicament is for use in the treatment of T-cell mediated inflammation of the joints by a method which includes simultaneous or sequential administration of another immunosuppressive antibody.
30
9. Use according to Claim 8, wherein said other immunosuppressive antibody is an anti-CD4 antibody.
35
10. Use according to any of Claims 1 to 8, wherein the

medicament is for use in the treatment of T-cell mediated inflammation of the joints by a method which includes simultaneous or sequential administration of a steroid.

5 11. An agent for use in the treatment of T-cell mediated inflammation of the joints, which agent comprises an antibody recognising the CDw52 antigen.

10 12. An agent according to Claim 11, wherein said antibody is a humanised antibody.

13. An agent according to Claim 12, wherein said antibody is CAMPATH-1H.

15 14. An agent according to any of Claims 11 to 13, for use in the treatment of rheumatoid arthritis.

20 15. An agent according to any of Claims 11 to 14, wherein in said treatment the antibody is administered in an amount of from 1 to about 100mg per day for a period between 1 and 30 days.

25 16. An agent according to Claim 15, wherein said amount is 1 to 10mg per day.

17. An agent according to any of Claims 11 to 16, adapted to be administered intravenously.

30 18. An agent according to any of Claims 11 to 17, for use in the treatment of T-cell mediated inflammation of the joints by a method which includes simultaneous or sequential administration of another immunosuppressive antibody.


35 19. An agent according to Claim 18, wherein said other immunosuppressive antibody is an anti-CD4 antibody.

20. An agent according to any of Claims 11 to 18, for use in the treatment of T-cell mediated inflammation of the joints by a method which includes simultaneous or sequential administration of a steroid.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 92/01884

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61K39/395; //(A61K39/395,31:705)		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07K ; A61K	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	CLINICAL RESEARCH vol. 38, no. 2, April 1990, THOROFARE NJ, USA page 268A P. MATHIESON ET AL. 'Monoclonal antibody therapy in systemic vasculitis.'	1-4, 10-14,20
Y	see abstract	8,9,18, 19
Y	WO,A,9 110 722 (CENTOCOR, INC.) 25 July 1991 see claims	8,9,18, 19
X	EP,A,0 328 404 (MEDICAL RESEARCH COUNCIL) 16 August 1989 see claims	1-4, 8-14, 18-20
	-/-	
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 12 JANUARY 1993		Date of Mailing of this International Search Report 16.02.93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer NOOIJ F.J.M. 

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	WO,A,9 207 084 (THE WELLCOME FOUNDATION LIMITED) 30 April 1992 see claims ---	1-4, 8-14, 18-20
P,X	THE LANCET vol. 340, no. 8822, 26 September 1992, LONDON, GB pages 748 - 752 J. ISAACS ET AL. 'Humanised monoclonal antibody therapy for rheumatoid arthritis.' see abstract ---	1-4, 8-14, 18-20
P,X	JOURNAL OF RHEUMATOLOGY vol. 18, no. 11, November 1991, TORONTO, CANADA pages 1737 - 1738 V. KYLE ET AL. 'Humanized monoclonal antibody treatment in rheumatoid arthritis.' see abstract -----	1-4, 8-14, 18-20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB92/ 01884

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 5-7, 15-17
because they relate to subject matter not required to be searched by this Authority, namely:
see PCT-Rule 39.1(iv)
Remark: Claims 8-10, 18-20 are searched as far as PCT-Rule 39.1(iv) was not concerned.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9201884
SA 65912

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 12/01/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9110722	25-07-91	CA-A- 2070182	28-06-91
		EP-A- 0511308	04-11-92
EP-A-0328404	16-08-89	AU-A- 3062689	06-09-89
		WO-A- 8907452	24-08-89
		GB-A, B 2216126	04-10-89
WO-A-9207084	30-04-92	AU-A- 8729491	20-05-92
		EP-A- 0504363	23-09-92
		FR-A- 2668164	24-04-92
		GB-A- 2253397	09-09-92

EP FORM PCT/93

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82